Fundraising Fox
Luxembourg · Seed–Series B · 40 people tracked
Find your way into Droia Ventures
Sign up to see every warm intro you have to Droia Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Droia Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Droia backs young drug development companies whose technology platforms or scientific insights can address previously unsolvable clinical problems, focusing exclusively on oncology and genetic disease therapeutics. Success is measured by patient benefit relative to unmet medical need and improvement over standard of care. The firm is a hands-on investor and company builder, supporting portfolio companies from formation through clinical proof of concept via an in-house team of drug development experts, sometimes taking interim operating roles. Droia Labs, its scientific arm, validates novel ideas and provides research facilities. The firm invests in existing companies and also creates new ones from the ground up alongside founders and management teams.
Source: firm website, verified Sep 27, 2026.
Team · 40 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Droia Ventures went on to found or lead other companies.
What they invest in
from 31 of 36 portfolio companiesBiotech ×27Healthtech ×18Deep Tech ×10Medical Devices ×9AI & Machine Learning ×7Digital Health ×3B2B Marketplaces ×2Longevity ×2
HQs:United States×14Belgium×2Colombia×2Switzerland×1Netherlands×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×22 founders×93 founders×24+ founders×1
Where their founders studiedfrom 19 founders with education data
Imperial College London ×2Massachusetts Institute of Technology ×2University of Michigan ×2
What their founders studiedfrom 18 founders with field-of-study data
Life Sciences ×10Chemistry ×5Medicine ×2
Where their founders worked beforefrom 21 founders with career history
Atlas Venture ×2Flexus Biosciences ×2
Investments · 36 tracked
founders shown can be your intro pathBy year:2025 · 42024 · 42022 · 12021 · 62020 · 12019 · 117 dated
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersForesite CapitalJazzya InvestmentsMedicxi+6 more
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)in
Board seatJanwillem NaesensMatthias Van Woensel· per SEC Form D
Co-investorsEisai Innovation, Inc.Novartis Venture FundRA Capital
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Judo Bio Co-Founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(Executive Chair and Acting CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesThe Column GroupYK Bioventures
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture InvestmentsPolaris Partners
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture Investments
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalVida VenturesCatalio Capital ManagementPolaris Partners
.jpeg){kind=logo}
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatJanwillem Naesens· per SEC Form D
Co-investorsInkefMission BiocapitalMRL Ventures FundNextech InvestRA Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatLuc Dochez· per SEC Form D
Co-investorsALS Investment FundDolby Family VenturesInkefMC Healthcare VenturesMission BiocapitalMitsui Global Investment+8 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
Actio is a precision medicine company developing therapeutics by leveraging genetic insights to treat rare diseases and common conditions at their molecular root.
AI & Machine LearningBiotech
Co-investorsCanaan PartnersDeerfield Management Company
Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.
BiotechDeep Tech
David Breckenridge(Founder)inDavid B. Goldstein(Founder)
Co-investorsCanaan PartnersEcoR1 Capital
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsFrazier Life SciencesNovartis Venture FundRV Invest GmbHFrazier Healthcare PartnersMPM BioImpactRTW Investments L.P.+1 more
Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.
BiotechHealthtech
Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalForesite CapitalGV (Google Ventures)SLVC+4 more
Cristal Therapeutics develops therapeutics in the life sciences sector.
BiotechDeep TechDigital HealthMedical DevicesUtrecht, NL
Dr. Cristianne Rijcken(Chief Scientific Officer and Founder)Dr. Joost Holthuis(Co-founder and former CEO)
Co-investorsBioGeneration VenturesChemelot VenturesThuja CapitalBOMBrightlands Venture Partners
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo VenturesJanus Henderson Investors+3 more
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Felicis VenturesMPM BioImpactRA CapitalDCVC Bio+2 more
Highlight Therapeutics is a biotech company developing therapeutic treatments.
BiotechHealthtech
Marisol Quintero(Chief Operating Officer (former CEO 2013-2025))in
Co-investorsBuenavista Equity PartnersColumbus Venture Partners
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc VenturesFrazier Healthcare Partners
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesFrazier Healthcare PartnersNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+6 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Founder)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsHBM Healthcare InvestmentsHBM PartnersHealthCapMitsui Global InvestmentVenrock
Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.
BiotechDeep TechHealthtechLongevity
Rita Balice-Gordon(Founder)inJoachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)inMichel Detheux(Chief Executive Officer & Board Director)inAnders Hinsby(Chief Operating Officer)inNiels Plath(Chief Scientific Officer)inJakob Busch-Petersen(Chief Development Officer)in
Co-investorsSanofi VenturesSofinnova PartnersV-Bio Ventures
Developing highly selective MET kinase inhibitors (Beerse, Belgium).
Co-investorsOmnes CapitalV-Bio Ventures
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)inRafael Casabianca
Co-investorsNovartis Venture FundY CombinatorDigitalis VenturesForbionGlilot Capital PartnersGlobal Founders Capital+7 more
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more
Roche develops diagnostics and pharmaceutical medicines to address major healthcare challenges and improve patient outcomes across prevention, treatment, and cure.
BiotechDigital HealthHealthtechMedical Devices
Unnatural Products is a drug discovery platform company that develops synthetic macrocycles to target previously undruggable disease targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Cruz, US
Cameron Pye(Co-Founder & CEO)inJoshua Schwochert(Co-Founder & CSO)in
BoardVasudev Bailey(Director)in
Co-investorsAbstract VenturesArtis VenturesAsset Management CompanyBetter Ventures Central LlcBlue Bear VenturesColorcon Ventures+8 more
.png)
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments.
BiotechHealthtechMedical Devices
Co-investorsMedicxiEQT Life SciencesGoldman Sachs
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalEQT Life SciencesEurazeoKurma PartnersPureos Bioventures
VICO is an online platform for finding verified furnished monthly housing — rooms, studios, and apartments — aimed at students, young professionals, and digital nomads relocating to a new city.
B2B MarketplacesConsumerMarketplacesPropTechTravel & HospitalityMedellín, CO
Manuel FranzinTilman Burfeindin
Co-investors500 GlobalEQT Life SciencesEurazeoKurma PartnersPureos Bioventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Summation BioHykuJudoSmall MoleculesVaderis
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 IPOsAura BiosciencesNASDAQ: AURA
Portfolio news
latest coverage across their companiesVaderis Therapeutics · finsmes.com · Aug 11, 2026
Unnatural Products · finance.yahoo.com · Mar 16, 2026
Frequently asked questions
- How many investments has Droia Ventures made?
- Droia Ventures has 36 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.
- What stage does Droia Ventures invest at?
- Droia Ventures invests at the Seed, Series A, Series B stages.
- What is Droia Ventures's typical check size?
- Droia Ventures typically writes checks of $540K.
- What sectors does Droia Ventures focus on?
- Droia Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Droia Ventures located?
- Droia Ventures is headquartered in Luxembourg, LU.
- Does Droia Ventures lead rounds?
- Droia Ventures typically participates in rounds rather than leading them.
- Who does Droia Ventures co-invest with?
- Droia Ventures most often shares deals with Frazier Life Sciences, Novartis Venture Fund, The Column Group, among 78 tracked co-investors.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.